Concenter BioPharma is currently raising funds for conducting this trial.

Concenter Biopharma granted approval for Phase 2a Clinical Trial at

Sheba Medical Center (Israel).


AWARDED FIRST PLACE

Zygosid-50 could be the first diabetes drug to restore near-normal cellular sensitivity to insulin, without side effects.

Concenter BioPharma is currently raising funds for conducting this trial. Concenter BioPharma's co-founder and CSO, Prof. Mottie (Mordechai) Chevion said: “the unique property of our drug candidate - Zygosid-50 is that it cancels out insulin resistance".









Hi, thanks for stopping by!

Concenter BioPharma is a subsidiary of Silkim Pharma Ltd., which developed a novel, protected PLATFORM of drugs for proven treatments of multiple indications. 

 

Our PLATFORM is the result of extensive investigation of animal models of human diseases.

Let the news
come to you.

  • LinkedIn
  • Facebook
  • Twitter

CONTACT US

Thank you for your interest in Concenter BioPharma.

To contact us please reach us via: